| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPRY3 |
| Uniprot No | O43610 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-288aa |
| 氨基酸序列 | MDAAVTDDFQ QILPIEQLRS THASNDYVER PPAPCKQALS SPSLIVQTHK SDWSLATMPT SLPRSLSQCH QLQPLPQHLS QSSIASSMSH STTASDQRLL ASITPSPSGQ SIIRTQPGAG VHPKADGALK GEAEQSAGHP SEHLFICEEC GRCKCVPCTA ARPLPSCWLC NQRCLCSAES LLDYGTCLCC VKGLFYHCST DDEDNCADEP CSCGPSSCFV RWAAMSLISL FLPCLCCYLP TRGCLHLCQQ GYDSLRRPGC RCKRHTNTVC RKISSGSAPF PKAQEKSV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SPRY3重组蛋白的参考文献概览(虚构示例，仅供参考格式)：
1. **标题**：*Structural and functional analysis of SPRY3 recombinant protein in cancer signaling*
**作者**：Chen L, et al.
**摘要**：研究通过重组表达纯化SPRY3蛋白，解析其晶体结构，揭示其通过抑制MAPK通路抑制肺癌细胞增殖的分子机制。
2. **标题**：*SPRY3 recombinant protein modulates neuronal development in autism models*
**作者**：Kim S, Patel R.
**摘要**：利用重组SPRY3蛋白处理小鼠神经元细胞，发现其通过调节FGF信号通路改善自闭症模型中的突触发育异常。
3. **标题**：*High-yield production of bioactive SPRY3 in E. coli: Optimization and validation*
**作者**：Wang Y, et al.
**摘要**：报道通过大肠杆菌表达系统优化SPRY3重组蛋白生产工艺，验证其体外抑制肿瘤迁移的生物活性，为临床前研究提供基础。
注：以上为模拟内容，实际文献需通过PubMed/Google Scholar检索关键词“SPRY3 recombinant protein”获取。
SPRY3 (SPRY domain-containing protein 3) is a member of the SPRY protein family, characterized by a conserved SPRY domain that mediates protein-protein interactions. This domain, originally identified in *SP*la and *RY*anodine receptor proteins, plays a critical role in regulating cellular signaling pathways, particularly those involving receptor tyrosine kinases (RTKs) and growth factor signaling. SPRY3 is implicated in modulating MAPK (mitogen-activated protein kinase) and PI3K-AKT pathways, influencing processes such as cell proliferation, differentiation, and apoptosis.
The recombinant SPRY3 protein is produced using genetic engineering techniques, typically expressed in bacterial (e.g., *E. coli*) or mammalian cell systems to ensure proper folding and post-translational modifications. Its recombinant form enables researchers to study its molecular interactions, structural properties, and functional roles in vitro or in cellular models. SPRY3 has drawn attention in cancer research due to its dual role as both a potential tumor suppressor and promoter, depending on cellular context. For instance, it may inhibit RTK signaling in certain cancers while promoting metastasis in others.
Additionally, SPRY3 is linked to neurodevelopmental disorders. Studies suggest its involvement in neural circuit formation, with mutations or dysregulation associated with autism spectrum disorders (ASD) and intellectual disabilities. Recombinant SPRY3 proteins are valuable tools for investigating these mechanisms, screening therapeutic compounds, or developing diagnostic biomarkers. Their applications extend to studying cilia function, immune responses, and tissue development. Despite progress, the precise molecular mechanisms of SPRY3 remain partially unresolved, necessitating further research to clarify its context-dependent roles and therapeutic potential.
×
